Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. In addition, this antibiotic formulation has activity on biofilms. The combination also has activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This formulation is administered using a single-patient use, vibrating-plate nebulizer that is compatible with all ventilators. The nebulizer creates small, uniform aerosol droplets that deliver drug to the small airways and alveoli. Integration of this novel antibiotic formulation and device has the potential to achieve significant clinical outcomes relative to current standard therapy.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Drugrecure ApS, a subsidiary of Savara, Inc., is a Danish company that provides health care services.

Inspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development.

Barts and The London hospitals produce some of the best clinical outcomes in the UK - evidenced by one of the best survival rate records in the NHS.\nT\nheir world renowned hospitals have made and continue to make an outstanding contribution to modern medicine.\nTheir hospitals' full portfolio of specialist centers includes the country's biggest heart attack centre, leading edge cancer specialties, one of the UK's largest children's hospitals and a highly successful fertility centre. Home to London's air ambulance, Barts and The London is also one of the capital's leading trauma and emergency care centers.

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections.

Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.

Seoul National University Bundang Hospital (분당 서울대병원) is located in Gumi-dong, Bundang, Seongnam, Gyeonggi-do, South Korea. It began its first treatment on 10 May 2003. It was set up due to a rapid increase in demand for geriatric treatment and the government's request for the establishment of a medical facility for local residents.

Nanjing Drum Tower Hospital is a private company headquartered in China. The firm provides medical services.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "cortical remapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.

Techno-Sciences, Inc. (TSi), is a provider of SAR satellite ground stations, integrated emergency response center systems and coastal surveillance solutions. TSi has been instrumental in the development of the COSPAS-SARSAT international satellite-based SAR program, which has helped to save over 35,000 lives worldwide since 1982. TSi is also actively involved in the next-generation COSPAS-SARSAT system, MEOSAR (Medium Earth Orbit Search and Rescue), which will greatly improve the existing SAR process with near-instantaneous detection, identification and location of emergency distress beacons.

Suzhou MedicalSystem Technology Co., Ltd. provides overall solutions and application software products for clinical information systems (CIS). Its products include series of clinical medical management information system software such as anesthesia CIS, intensive care CIS, pre-hospital emergency information systems, blood purification systems, and clinical path information systems. Its overall clinical information solutions include digital operating room overall solutions, digital ward solutions, and digital emergency first aid platform solutions. The company was founded on August 14, 2009 and is headquartered in Suzhou, China.

Dongguan Yongsheng Medical Technology Co., Ltd., established on 2017-12-01, Business scope includes research and development,Production,Sales:medical instruments(including a class of medical devices,Class II medical devices and Class III medical devices),Medical sewing products,Health care products,electronic product,household appliances;Import and export.(The above projects do not involve special management measures for foreign investment access)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)